CARsgen Therapeutics Holdings Limited (HKG:2171)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
19.10
+2.50 (15.06%)
May 13, 2025, 3:45 PM HKT
209.56%
Market Cap 9.14B
Revenue (ttm) 41.95M
Net Income (ttm) -849.35M
Shares Out 550.40M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,611,501
Average Volume 2,196,250
Open 16.60
Previous Close 16.60
Day's Range 16.60 - 19.62
52-Week Range 2.48 - 19.78
Beta 0.38
RSI 59.97
Earnings Date May 28, 2025

About HKG:2171

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clini... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 465
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2171
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.